iatroX logo
brainstormaskiatroXuk q-bankus q-bankknowledge centreblog
Knowledge Centre / Anthrax

Anthrax

Recognition and management of Anthrax.

Reviewed by Dr Kola Tytler MBBS CertHE MBA MRCGP (General Practitioner)
Last reviewed: 21 October 2025
Infectious DiseasesPublic Health

Clinical Guidelines

Anthrax | Treatment summaries | BNF | NICE
National
European Guidelines for the clinical management of anthrax and bioterrorism-related anthrax
National
Guidelines for the Surveillance and Control of Anthrax in Humans and Animals
National
Anthrax as a Biological Weapon, 2002: Updated Recommendations for Management
Local
Anthrax in Humans and Animals (WHO Guidelines)
Local
Anthrax in Pregnant and Postpartum Women (ACOG Endorsed Guidance)
Local
Anthrax: Developing Drugs for Prophylaxis of Inhalational Anthrax Guidance for Industry
Local
Anthrax: implementation guidance for clinicians
Local
CDC Guidelines for the Prevention and Treatment of Anthrax, 2023
Local
Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections (IDSA)
Local

Recent iatroX Q&As

  • What laboratory investigations are recommended for confirming a diagnosis of anthrax in primary care?Updated: 8/17/2025
  • When should I consider referring a patient with suspected anthrax to a specialist or infectious disease unit?Updated: 8/17/2025
askiatroX
privacytermshow it workscpdinsightsfaqabout
UKCA Mark

iatroX is a UKCA-marked, MHRA-registered medical device.

Download on the App StoreGet it on Google Play